Paper - WANFANG MED ONLINE

You Position: Home > Paper

Advances in roles of prokinetic agents in the treatment of gastroesophageal reflux disease

( views:341, downloads:147 )

Author:: No author available

Journal Title:: WORLD CHINESE JOURNAL OF DIGESTOLOGY

Issue:: 7

DOI:: 10.3969/j.issn.1009-3079.2008.07.011

Key Word:: 促动力药物;胃食管反流病;治疗;莫沙必利

Abstract：胃食管反流病(gastroesophageal reflux disease,GERD)是由胃内容物反流引起不适症状和(或)并发症的一种疾病.GERD的发病机制包括食管下括约肌(lower esophageal sphincter,LES)功能失调,食管对反流物廓清能力下降,胃排空延迟以及食管黏膜对胃酸的抵抗力异常.因此,恢复胃动力、增强LES收缩以及食管运动的促动力药物常被用于治疗GERD,包括甲氧氯普胺、多潘立酮、西沙必利及莫沙必利等药物.目前认为,对于治疗轻度GERD促动力药物与H2受体阻滞剂具有相同的疗效,而在治疗重症GERD时促动力药物和抑酸药物联合治疗比单药治疗更有效.本文就将促动力药物在GERD治疗方案中作用和地位的研究进展作一综述.

Reference

[1]王海勇,俞杏萍,郁敏敏,等.莫沙必利治疗反流性食管炎的近期疗效[J].2002,(10).
[2]Yong Sung Kim,Tae Hyeon Kim,Chang Soo Choi,etc.Effect of itopride, a new prokinetic, in patients with mild GERD: A pilot study[J].2005,(27).
[3]许军英,谢小平,侯晓华.食管运动功能在重度反流性食管炎中的地位[J].2005,(5).
[4]周慧芬.雷贝拉唑、枸橼酸莫沙比利联用治疗反流性食管炎的疗效观察[J].2006,(9).
[5]袁晓英,王丹,向明确,等.奥美拉唑与莫沙比利联合治疗中、重度反流性食管炎疗效观察[J].2006,(5).
[6]林三仁,许国铭,胡品津,等.中国胃食管反流病共识意见2006年10月三亚[J].2007,(4).
[7]孙晓红,柯美云,王智凤,等.胃食管反流病维持治疗方式的影响因素分析[J].2004,(8).
[8]王泽衍,柏乃运.枸橼酸莫沙比利片治疗反流性食管炎疗效观察[J].2006,(10).
[9]李兆申,王雯,许国铭,等.反流性食管炎1 827例临床分析[J].2001,(1).
[10]刘明东,徐肇敏,陈隆典.枸橼酸莫沙比利治疗反流性食管炎的疗效[J].2003,(6).
[11]Kenneth R, DeVault,Donald O, Castell.Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease.[J].2005,100(1).
[12]Q, Zhang,A, Lehmann,R, Rigda,etc.Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease.[J].2002,50(1).
[13]Talley NJ,Zinsmeister AR,Choung RS,etc.A double-blind, randomized, placebo-controlled trial of itopride (100 and 200 mg three times daily) on gastric motor and sensory function in healthy volunteers.[J].2007,19(3).
[14]Amarapurkar DN,Rane P.Randomised, double-blind, comparative study to evaluate the efficacy and safety of ganaton (itopride hydrochloride) and mosapride citrate in the management of functional dyspepsia.[J].2004,102(12).
[15]F, De Giorgi,M F, Savarese,E, Atteo,etc.Medical treatment of gastro-oesophageal reflux disease.[J].2006,26(5).
[16]Achem S.R.,Robinson M..A Prokinetic Approach to Treatment of Gastroesophageal Reflux Disease[J].1998,16(1).
[17]M, Ruth,B, Hamelin,K, R?hss,etc.The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease.[J].1998,12(1).
[18]J.-P. Galmiche,P. Barthelemy,B. Hamelin.Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride[J].1997,11(4).
[19]Tonini M,De Ponti F,De Giorgio R.Progress with Novel Pharmacological Strategies for Gastro-oesophageal Reflux Disease.[J].2004,64(4).
[20]Talley NJ,Adam B,Holtmann G,etc.A placebo-controlled trial of itopride in functional dyspepsia.[J].2006,354(8).
[21]Galmiche JP,Coron E,Hatlebakk JG.Medical therapy of gastroesophageal reflux disease.[J].2007,23(4).
[22]Lundell L,Cange L,Finizia C,etc.The effect of mosapride on oesophageal motor function and acid reflux in patients with gastro-oesophageal reflux disease.[J].2003,15(10).
[23]Chiba T,Terui T,Ikeda K,etc.Effects of itopride hydrochloride and ranitidine in patients with functional dyspepsia: comparison between prokinetic and acid suppression therapies.[J].2007,54(78).
[24]McCullough JL,Beattie DT,Armstrong SR.Measurement of 5-HT4 receptor-mediated esophageal responses by digital sonomicrometry in the anesthetized rat.[J].2006,53(3).
[25]Proskin HM,Shetzline MA,Rodriguez Stanley S,etc.Effect of tegaserod on esophageal pain threshold, regurgitation, and symptom relief in patients with functional heartburn and mechanical sensitivity.[J].2006,4(4).
[26]Kuwabara M,Tanaka M,Okamoto T,etc.Long-term gastroesophageal reflux disease therapy improves reflux symptoms in elderly patients: five-year prospective study in community medicine.[J].2007,22(5).
[27]J M, Inadomi,R, Jamal,G H, Murata,etc.Step-down management of gastroesophageal reflux disease.[J].2001,121(5).
[28]Chandra KM,Harding SM.Therapy Insight: treatment of gastroesophageal reflux in adults with chronic cough.[J].2007,4(11).
[29]G H, Koek,D, Sifrim,T, Lerut,etc.Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors.[J].2003,52(10).
[30]DeVault KR,Ferguson DD.Medical management of gastroesophageal reflux disease.[J].2007,8(1).
[31]Davita, Hammer.Gastroesophageal reflux and prokinetic agents.[J].1900,24(2).
[32]Finizia Caterina,Lundell Lars,Ruth Magnus,etc.The effect of cisapride on oesophageal motility and lower sphincter function in patients with gastro-oesophageal reflux disease.[J].2002,14(1).
[33]Piche T,Galmiche JP.Pharmacological targets in gastro-oesophageal reflux disease.[J].2005,97(6).
[34]Bargaje RS,Kulkarni SS,Walwaikar PP.Evaluation of new gastro-intestinal prokinetic (ENGIP-I) study.[J].2005,103(10).
[35]Cho YK,Choi MG,Han HW,etc.The effect of mosapride on esophageal motility and bolus transit in asymptomatic volunteers.[J].2006,40(4).
[36]Smout AJ.Advantages and disadvantages of lumping together gastroesophageal reflux disease and dyspepsia.[J].2006,22(4).
[37]Tutuian R,Allan R,Agrawal A,etc.Effects of a 5-HT receptor agonist on oesophageal function and gastro-oesophageal reflux: studies using combined impedance-manometry and combined impedance-pH.[J].2006,24(1).
[38]Tack J.Recent developments in the pathophysiology and therapy of gastroesophageal reflux disease and nonerosive reflux disease.[J].2005,21(4).
[39]de-Caestecker John.Prokinetics and reflux: a promise unfulfilled.[J].2002,14(1).
[40]Armstrong D.Gastroesophageal reflux disease.[J].2005,5(6).
[41]N, Yoshida.[Pharmacological effects of the gastroprokinetic agent mosapride citrate].[J].1999,113(5).
[42]Mizuta Y,Shikuwa S,Isomoto H,etc.Recent insights into digestive motility in functional dyspepsia.[J].2006,41(11).
[43]Sharma MP,Madan K,Ahuja V,etc.Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial.[J].2004,17(4).
[44]Walwaikar PP,Kulkarni SS,Bargaje RS.Evaluation of new gastro-intestinal prokinetic (ENGIP-II) study.[J].2005,103(12).
[45]Fox M,Stutz B,Fried M,etc.The effects of tegaserod on oesophageal function and bolus transport in healthy volunteers: studies using concurrent high-resolution manometry and videofluoroscopy.[J].2006,24(7).
[46]M A, Van Herwaarden,M, Samsom,C H, Van Nispen,etc.The effect of motilin agonist ABT-229 on gastro-oesophageal reflux, oesophageal motility and lower oesophageal sphincter characteristics in GERD patients.[J].2000,14(4).